HUTCHMED (China) Ltd: Form 20-F for the period ended Dec 31, 2022
Filed with the SEC on Feb 28, 2023 and accepted by EDGAR at Feb 28, 2023, 06:07 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-01-01 to 2022-12-31 | $426.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2022-01-01 to 2022-12-31 | $386.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$407.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $652.0k | us-gaap:InterestExpense |
| Income tax | 12 months2022-01-01 to 2022-12-31 | −$283.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$360.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | −$0.43 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$0.43 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 847,143,540 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$268.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $36.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2022-01-01 to 2022-12-31 | $48.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-12-31 | $313.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $839.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $1.03bn | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $353.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $392.6m | us-gaap:Liabilities |
| Long-term debt | At period end2022-12-31 | $18.1m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2022-12-31 | $610.4m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2022-12-31 | 864,775,340 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001104659-23-026282. Last ingested by Listed: Nov 2, 2026, 06:07 ET. Listed shows no prices and gives no investment advice.